search
Back to results

Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty

Primary Purpose

Plastic Surgery, Mammaplasty, Anti-bacterial Agents

Status
Recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Cephazolin
Sterile saline
Sponsored by
Daniela Francescato Veiga
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Plastic Surgery

Eligibility Criteria

18 Years - 60 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 and 60 years of age
  • body mass index (BMI) between 19 and 30 kg/m2
  • breast hypertrophy according to the criteria of Sacchini et al. and Franco and Rebello

Exclusion Criteria:

  • patients who had previously undergone another surgical procedure of the breast
  • patients who have been diagnosed with a breast pathology
  • smokers
  • patients who had a child or breastfed within the last year
  • patients with uncontrolled comorbidities, such as arterial hypertension or diabetes
  • use of immunosuppressants
  • patients who had any infection during the follow-up period, requiring the use of antibiotics
  • patients who present any adverse effects due to the antibiotics during the study
  • patients who miss follow-up assessments
  • patients who withdraw their consent at any time

Sites / Locations

  • Hospital das Clinicas Samuel Libânio, Universidade do Vale do SapucaíRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Cephazolin

Sterile saline

Arm Description

Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours

Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours

Outcomes

Primary Outcome Measures

Number of patients with surgical site infection (SSI)
Patients will be monitored for the occurrence of SSI once weekly during the first 30 days following hospital discharge by a single surgeon who is blinded to their treatment group. SSI will be evaluated based on the definition adopted by the Centers for Disease Control and Prevention.

Secondary Outcome Measures

Full Information

First Posted
September 3, 2019
Last Updated
July 25, 2022
Sponsor
Daniela Francescato Veiga
search

1. Study Identification

Unique Protocol Identification Number
NCT04079686
Brief Title
Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty
Official Title
Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty: a Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 5, 2019 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Daniela Francescato Veiga

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Setting: Translacional Surgery Graduation Program - Universidade Federal de São Paulo and Hospital das Clínicas Samuel Libânio - Universidade do Vale do Sapucaí. Background: Breast reduction is one of the most performed plastic surgery procedures. Antibiotics are widely prescribed, on an empirical basis, to prevent surgical site infections. However, there is a lack of evidence to support its use. Objective: To compare the influence of the use of prophylatic antibiotics as a single dose or for 24 hours on surgical site infection rates following reduction mammaplasty. Methods: Randomized trial of non-inferiority, with two parallel groups, double blinded. A total of 146 breast hypertrophy patients, with reduction mammaplasty already scheduled, will be enrolled. Patients will be randomly allocated to group A, that will receive antibiotics only at the anesthesia induction (n=73), or to group B, that will receive antibiotics at the anesthesia induction and for 24 hours (n=73). None of the patients will receive antibiotics after hospital discharge. Patients will be followed-up weekly, for 30 days, regarding surgical site infection. The Centers for Disease Control and Prevention criteria will be applied. A statistical analysis of the data will be performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Plastic Surgery, Mammaplasty, Anti-bacterial Agents, Prophylaxis, Wound Infection

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
146 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cephazolin
Arm Type
Experimental
Arm Description
Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours
Arm Title
Sterile saline
Arm Type
Placebo Comparator
Arm Description
Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours
Intervention Type
Drug
Intervention Name(s)
Cephazolin
Intervention Description
Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
Intervention Type
Other
Intervention Name(s)
Sterile saline
Intervention Description
Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
Primary Outcome Measure Information:
Title
Number of patients with surgical site infection (SSI)
Description
Patients will be monitored for the occurrence of SSI once weekly during the first 30 days following hospital discharge by a single surgeon who is blinded to their treatment group. SSI will be evaluated based on the definition adopted by the Centers for Disease Control and Prevention.
Time Frame
30 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 and 60 years of age body mass index (BMI) between 19 and 30 kg/m2 breast hypertrophy according to the criteria of Sacchini et al. and Franco and Rebello Exclusion Criteria: patients who had previously undergone another surgical procedure of the breast patients who have been diagnosed with a breast pathology smokers patients who had a child or breastfed within the last year patients with uncontrolled comorbidities, such as arterial hypertension or diabetes use of immunosuppressants patients who had any infection during the follow-up period, requiring the use of antibiotics patients who present any adverse effects due to the antibiotics during the study patients who miss follow-up assessments patients who withdraw their consent at any time
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Daniela F Veiga, MD, PhD
Phone
55-11-55764848
Ext
3054
Email
danielafveiga@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Joel Veiga-Filho, MD, PhD
Phone
55-35-34232502
Email
veigafilhoj@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniela F Veiga, MD, PhD
Organizational Affiliation
Federal University of Sao Paulo
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital das Clinicas Samuel Libânio, Universidade do Vale do Sapucaí
City
Pouso Alegre
State/Province
MG
ZIP/Postal Code
37550000
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniela F Veiga, MD, PhD
Phone
55-35-34492199
Email
danielafveiga@gmail.com
First Name & Middle Initial & Last Name & Degree
Joel Veiga-Filho, MD, PhD
Phone
55-35-34232502
Email
veigafilhoj@gmail.com
First Name & Middle Initial & Last Name & Degree
Joel Veiga-Filho, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32616026
Citation
Veiga DF, da Silva Garcia E, Moreira-Filho JW, de Mattos Andrade EB, Juliano Y, Veiga-Filho J, Ferreira LM. Single dose versus 24 h antibiotic prophylaxis in reduction mammaplasty: study protocol for a randomized controlled trial. Trials. 2020 Jul 2;21(1):605. doi: 10.1186/s13063-020-04539-0.
Results Reference
background
Links:
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331275/pdf/13063_2020_Article_4539.pdf
Description
Study Protocol

Learn more about this trial

Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty

We'll reach out to this number within 24 hrs